© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 3, 259-263,
February 3, 1999
© 1999 Oxford University Press
REPORTS |
Survival After Breast Cancer in Ashkenazi Jewish BRCA1 and BRCA2 Mutation Carriers
Affiliations of authors: J. S. Lee, Howard Hughes Medical Institute, Bethesda, MD, and Division of Cancer Epidemiology and Genetics, National Cancer Institute (NCI), Bethesda; S. Wacholder, J. P. Struewing, M. A. Tucker, P. Hartge, Division of Cancer Epidemiology and Genetics, NCI; M. McAdams, D. Pee, Information Management Services Inc., Silver Spring, MD; L C. Brody, Genetics and Molecular Biology Branch, National Human Genome Research Institute, Bethesda.
Correspondence to: Patricia Hartge, Sc.D., National Institutes of Health, Executive Plaza North, Rm. 443, Bethesda, MD 20852 (e-mail: hartge{at} nih.gov).
BACKGROUND: Studies of survival following breast and ovarian cancers in BRCA1 and/or BRCA2 mutation carriers have yielded conflicting results. We undertook an analysis of a community-based study of Ashkenazi Jews to investigate the effect of three founder mutations in BRCA1 and BRCA2 on survival among patients with breast or ovarian cancer. METHODS: We collected blood samples and questionnaire data from 5318 Ashkenazi Jewish volunteers. The blood samples were tested for 185delAG (two nucleotide deletion) and 5382insC (single nucleotide insertion) mutations in BRCA1 and the 6174delT (single nucleotide deletion) mutation in BRCA2. To estimate survival differences in the affected relatives according to their BRCA1 and/or BRCA2 mutation carrier status, we devised and applied a novel extension of the kin-cohort method. RESULTS: Fifty mutation carriers reported that 58 of their first-degree relatives had been diagnosed with breast cancer and 10 with ovarian cancer; 907 noncarriers reported 979 first-degree relatives with breast cancer and 116 with ovarian cancer. Kaplan-Meier estimates of median survival after breast cancer were 16 years (95% confidence interval [CI] = 11-40) in the relatives of carriers and 18 years (95% CI = 15-22) in the relatives of noncarriers, a difference that was not statistically significant (two-sided P = .87). There was also no difference in survival times among the 126 first-degree relatives with ovarian cancer. We found no survival difference between patients with breast or ovarian cancer who were inferred carriers of BRCA1 and/or BRCA2 mutations and noncarriers. CONCLUSIONS: Carriers of BRCA1 and BRCA2 mutations appeared to have neither better nor worse survival prognosis.
1 Breast Cancer Information Core site http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/Bic/>
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. M. Lee, D. B. Kopans, P. M. McMahon, E. F. Halpern, P. D. Ryan, M. C. Weinstein, and G. S. Gazelle Breast Cancer Screening in BRCA1 Mutation Carriers: Effectiveness of MR Imaging--Markov Monte Carlo Decision Analysis Radiology, March 1, 2008; 246(3): 763 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Hartge Genes, Cancer Risks, and Clinical Outcomes N. Engl. J. Med., July 12, 2007; 357(2): 175 - 176. [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Jacobi, N. J.D. Nagelkerke, J. C. van Houwelingen, and G. H. de Bock Breast Cancer Screening, Outside the Population-Screening Program, of Women from Breast Cancer Families without Proven BRCA1/BRCA2 Mutations: a Simulation Study. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 429 - 436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. van Roosmalen, L. C.G. Verhoef, P. F.M. Stalmeier, N. Hoogerbrugge, and W. A.J. van Daal Decision Analysis of Prophylactic Surgery or Screening for BRCA1 Mutation Carriers: A More Prominent Role For Oophorectomy J. Clin. Oncol., April 15, 2002; 20(8): 2092 - 2100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. J. Vaziri, L. M. Krumroy, P. Elson, G. T. Budd, G. Darlington, J. Myles, R. R. Tubbs, and G. Casey Breast Tumor Immunophenotype of BRCA1-Mutation Carriers Is Influenced by Age at Diagnosis Clin. Cancer Res., July 1, 2001; 7(7): 1937 - 1945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Buller, T. A. Lallas, M. S. Shahin, A. K. Sood, M. Hatterman-Zogg, B. Anderson, J. I. Sorosky, and P. A. Kirby The p53 Mutational Spectrum Associated with BRCA1 Mutant Ovarian Cancer Clin. Cancer Res., April 1, 2001; 7(4): 831 - 838. [Abstract] [Full Text]
|
|
|
|
|
|
D. Stoppa-Lyonnet, Y. Ansquer, H. Dreyfus, C. Gautier, M. Gauthier-Villars, E. Bourstyn, K. B. Clough, H. Magdelenat, P. Pouillart, A. Vincent-Salomon, et al. Familial Invasive Breast Cancers: Worse Outcome Related to BRCA1 Mutations J. Clin. Oncol., December 15, 2000; 18(24): 4053 - 4059. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Verhoog, E. M. J. J. Berns, C. T. M. Brekelmans, C. Seynaeve, E. J. Meijers-Heijboer, and J. G. M. Klijn Prognostic Significance of Germline BRCA2 Mutations in Hereditary Breast Cancer Patients J. Clin. Oncol., November 1, 2000; 18(90001): 119s - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. McGuire, A. S. Whittemore, R. Norris, and I. Oakley-Girvan Survival in Epithelial Ovarian Cancer Patients with Prior Breast Cancer Am. J. Epidemiol., September 15, 2000; 152(6): 528 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Schrag, K. M. Kuntz, J. E. Garber, and J. C. Weeks Life Expectancy Gains From Cancer Prevention Strategies for Women With Breast Cancer and BRCA1 or BRCA2 Mutations JAMA, February 2, 2000; 283(5): 617 - 624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Sellers, R. A. King, J. R. Cerhan, P.-L. Chen, D. M. Grabrick, L. H. Kushi, W. S. Oetting, R. A. Vierkant, C. M. Vachon, F. J. Couch, et al. Fifty-year Follow-Up of Cancer Incidence in a Historical Cohort of Minnesota Breast Cancer Families Cancer Epidemiol. Biomarkers Prev., December 1, 1999; 8(12): 1051 - 1057. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. H. Gail, D. Pee, and R. Carroll Kin-Cohort Designs for Gene Characterization J Natl Cancer Inst Monographs, December 1, 1999; 1999(26): 55 - 60. [Abstract] [Full Text]
|
|
|
|
|
|
L. C. Verhoog, C.T.M. Brekelmans, C. Seynaeve, G. Dahmen, A. N. van Geel, C.C.M. Bartels, M.M.A. Tilanus-Linthorst, A. Wagner, P. Devilee, D.J.J. Halley, et al. Survival in Hereditary Breast Cancer Associated With Germline Mutations of BRCA2 J. Clin. Oncol., November 1, 1999; 17(11): 3396 - 3402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-A. Phillips, I. L. Andrulis, and P. J. Goodwin Breast Carcinomas Arising in Carriers of Mutations in BRCA1 or BRCA2: Are They Prognostically Different? J. Clin. Oncol., November 1, 1999; 17(11): 3653 - 3663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Warner, W. Foulkes, P. Goodwin, W. Meschino, J. Blondal, C. Paterson, H. Ozcelik, P. Goss, D. Allingham-Hawkins, N. Hamel, et al. Prevalence and Penetrance of BRCA1 and BRCA2 Gene Mutations in Unselected Ashkenazi Jewish Women With Breast Cancer J Natl Cancer Inst, July 21, 1999; 91(14): 1241 - 1247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kaufman and J. P. Struewing Re: Effect of BRCA1 and BRCA2 on the Association Between Breast Cancer Risk and Family History J Natl Cancer Inst, July 21, 1999; 91(14): 1250 - 1251. [Full Text] [PDF]
|
|
|
|
|
|
W. Burke, N. Press, and L. Pinsky BRCA1 and BRCA2: a Small Part of the Puzzle J Natl Cancer Inst, June 2, 1999; 91(11): 904 - 905. [Full Text] [PDF]
|
|
|
|
|
|
W. Burke and M. B. Laya Genetic Risk and Breast Cancer Survival: Another Link in the Chain of Evidence J Natl Cancer Inst, February 3, 1999; 91(3): 201 - 203. [Full Text] [PDF]
|
|